MacroGenics argues that margetuximab works by tweaking the “Fc” part of Herceptin – the tail of the ‘Y’ shaped antibody – so that it interacts more efficiently with the immune system ...

MARGENZA (margetuximab-cmkb) is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors.

Margenza (margetuximab) won FDA approval in combination ... MacroGenics has altered the “Fc” part of the antibody – the tail of the ‘Y’-shaped molecule – so that it interacts more ...